Literature DB >> 26613897

Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Shinji Ozaki1, Raja Vuyyuru2, Ken Kageyama3, Mizue Terai3, Masahiro Ohara3, Hanyin Cheng4, Tim Manser2, Michael J Mastrangelo3, Andrew E Aplin4, Takami Sato5.   

Abstract

Uveal melanoma (UM) is a rare type of melanoma, although it is the most common primary ocular malignant tumor in adults. Nearly one-half the patients with primary UM subsequently develop systemic metastasis, preferentially to the liver. Currently, no treatment is effective for UM hepatic metastasis, and the prognosis is universally poor. The main challenge in designing a treatment strategy for UM hepatic metastasis is the lack of suitable animal models. We developed two orthotopic mouse models for human UM hepatic metastases: direct hepatic implantation model (intrahepatic dissemination model) and splenic-implantation model (hematogenous dissemination model) and investigated the tumorgenesis in the liver. A human UM cell line, established from a hepatic metastasis and nonobese diabetic severe combined immunodeficient γ mice, were used for development of in vivo tumor models. In the direct hepatic implantation model, a localized tumor developed in the liver in all cases and intrahepatic dissemination was subsequently seen in about one-half of cases. However, in the splenic implantation model, multiple hepatic metastases were observed after splenic implantation. Hepatic tumors subsequently seeded intra-abdominal metastasis; however, lung metastases were not seen. These findings are consistent with those observed in human UM hepatic metastases. These orthotopic mouse models offer useful tools to investigate the biological behavior of human UM cells in the liver.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26613897      PMCID: PMC4715216          DOI: 10.1016/j.ajpath.2015.09.011

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  66 in total

1.  VEGF as a biomarker for metastatic uveal melanoma in humans.

Authors:  Vivian Barak; Jacob Pe'er; Inna Kalickman; Shahar Frenkel
Journal:  Curr Eye Res       Date:  2011-02-01       Impact factor: 2.424

Review 2.  Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors.

Authors:  D Le Roith
Journal:  N Engl J Med       Date:  1997-02-27       Impact factor: 91.245

3.  Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumor size.

Authors:  I W McLean; K S Keefe; M N Burnier
Journal:  Ophthalmology       Date:  1997-05       Impact factor: 12.079

4.  Vascular endothelial growth factor a in eyes with uveal melanoma.

Authors:  Guy S O Missotten; Irene C Notting; Reinier O Schlingemann; Henry J Zijlmans; Chun Lau; Paul H C Eilers; Jan E E Keunen; Martine J Jager
Journal:  Arch Ophthalmol       Date:  2006-10

5.  Immunophenotypic differences between uveal and cutaneous melanomas.

Authors:  Satori Iwamoto; Robert C Burrows; Robert E Kalina; David George; Michael Boehm; Mark A Bothwell; Rodney Schmidt
Journal:  Arch Ophthalmol       Date:  2002-04

6.  An orthotopic model for human uveal melanoma in SCID mice.

Authors:  Arthur J Mueller; Andrew J Maniotis; William R Freeman; Dirk-Uwe Bartsch; Ulrich C Schaller; Germaine Bergeron-Lynn; Lingyun Cheng; Ibrahim Taskintuna; Xue Chen; June Kan-Mitchell; Robert Folberg
Journal:  Microvasc Res       Date:  2002-09       Impact factor: 3.514

7.  KIT gene mutations and copy number in melanoma subtypes.

Authors:  Carol Beadling; Erick Jacobson-Dunlop; F Stephen Hodi; Claudia Le; Andrea Warrick; Janice Patterson; Ajia Town; Amy Harlow; Frank Cruz; Sharl Azar; Brian P Rubin; Susan Muller; Rob West; Michael C Heinrich; Christopher L Corless
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

9.  Modeling the behavior of uveal melanoma in the liver.

Authors:  Robert Folberg; Lu Leach; Klara Valyi-Nagy; Amy Y Lin; Marsha A Apushkin; Zhuming Ai; Vivian Barak; Dibyen Majumdar; Jacob Pe'er; Andrew J Maniotis
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-07       Impact factor: 4.799

10.  Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.

Authors:  Mario A Economou; Charlotta All-Ericsson; Vladimir Bykov; Leonard Girnita; Armando Bartolazzi; Olle Larsson; Stefan Seregard
Journal:  Acta Ophthalmol       Date:  2008-11       Impact factor: 3.761

View more
  11 in total

1.  Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice.

Authors:  Ken Kageyama; Shinji Ozaki; Takami Sato
Journal:  J Vis Exp       Date:  2019-11-06       Impact factor: 1.355

2.  miRNA-145/miRNA-205 inhibits proliferation and invasion of uveal melanoma cells by targeting NPR1/CDC42.

Authors:  Yang Li; Jing-Ting Luo; Yue-Ming Liu; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2020-05-18       Impact factor: 1.779

Review 3.  Melanoma models for the next generation of therapies.

Authors:  E Elizabeth Patton; Kristen L Mueller; David J Adams; Niroshana Anandasabapathy; Andrew E Aplin; Corine Bertolotto; Marcus Bosenberg; Craig J Ceol; Christin E Burd; Ping Chi; Meenhard Herlyn; Sheri L Holmen; Florian A Karreth; Charles K Kaufman; Shaheen Khan; Sebastian Kobold; Eleonora Leucci; Carmit Levy; David B Lombard; Amanda W Lund; Kerrie L Marie; Jean-Christophe Marine; Richard Marais; Martin McMahon; Carla Daniela Robles-Espinoza; Ze'ev A Ronai; Yardena Samuels; Maria S Soengas; Jessie Villanueva; Ashani T Weeraratna; Richard M White; Iwei Yeh; Jiyue Zhu; Leonard I Zon; Marc S Hurlbert; Glenn Merlino
Journal:  Cancer Cell       Date:  2021-02-04       Impact factor: 31.743

4.  Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.

Authors:  Ken Kageyama; Masahiro Ohara; Kengo Saito; Shinji Ozaki; Mizue Terai; Michael J Mastrangelo; Paolo Fortina; Andrew E Aplin; Takami Sato
Journal:  J Transl Med       Date:  2017-06-23       Impact factor: 5.531

5.  Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.

Authors:  Daria Marley Kemp; Alyson Pidich; Mary Larijani; Rebecca Jonas; Elizabeth Lash; Takami Sato; Mizue Terai; Maria De Pizzol; Marcello Allegretti; Olga Igoucheva; Vitali Alexeev
Journal:  Oncotarget       Date:  2017-02-28

Review 6.  The biology of uveal melanoma.

Authors:  Adriana Amaro; Rosaria Gangemi; Francesca Piaggio; Giovanna Angelini; Gaia Barisione; Silvano Ferrini; Ulrich Pfeffer
Journal:  Cancer Metastasis Rev       Date:  2017-03       Impact factor: 9.264

7.  Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.

Authors:  Vivian Chua; Marlana Orloff; Jessica Lf Teh; Takahito Sugase; Connie Liao; Timothy J Purwin; Bao Q Lam; Mizue Terai; Grazia Ambrosini; Richard D Carvajal; Gary Schwartz; Takami Sato; Andrew E Aplin
Journal:  EMBO Mol Med       Date:  2019-02       Impact factor: 12.137

8.  Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma.

Authors:  Takahito Sugase; Bao Q Lam; Meggie Danielson; Mizue Terai; Andrew E Aplin; J Silvio Gutkind; Takami Sato
Journal:  J Transl Med       Date:  2020-05-20       Impact factor: 5.531

Review 9.  Animal Models of Uveal Melanoma: Methods, Applicability, and Limitations.

Authors:  Marta M Stei; Karin U Loeffler; Frank G Holz; Martina C Herwig
Journal:  Biomed Res Int       Date:  2016-06-06       Impact factor: 3.411

Review 10.  Mouse models of uveal melanoma: Strengths, weaknesses, and future directions.

Authors:  Jackson R Richards; Jae Hyuk Yoo; Donghan Shin; Shannon J Odelberg
Journal:  Pigment Cell Melanoma Res       Date:  2020-01-22       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.